Food News and Research

RSS

Patent infringement lawsuit regarding DHA in functional foods ruled in favor of Martek

Martek Biosciences Corporation (Nasdaq: MATK) announced today that a panel of judges on the United States Court of Appeals for the Federal Circuit has ruled in Martek's favor in appeal proceedings related to a patent infringement lawsuit between Martek and Lonza, Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties & Food Ingredients GmbH (collectively "Lonza").

9 Sep 2009

Care-Tech Laboratories consents to end illegal manufacture and marketing of OTC drugs

The U.S. Food and Drug Administration today announced that St. Louis-based Care-Tech Laboratories Inc. and its principal officers, John C. Brereton and Sherry L. Brereton, have signed a consent decree, agreeing to stop the illegal manufacture, marketing, and distribution of over-the-counter (OTC) antimicrobial drugs used to treat and prevent infection.

9 Sep 2009

Preliminary Phase 3 clinical study results of T-Pred released

ISTA Pharmaceuticals, Inc., today announced preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). The Company is developing T-Pred as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infection exists, or there is a risk of bacterial infection.

9 Sep 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.

9 Sep 2009

FDA approves the distribution of IMRISNV and IMRIScardio systems

IMRIS Inc. ("IMRIS" or the "Company") today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA), permitting the Company to market its newest products, IMRISNV and IMRIScardio in the United States.

9 Sep 2009

PKCiota oncogene essential for lung cancer stem cell proliferation

Scientists at the Mayo Clinic campus in Florida have found that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumors and are resistant to chemotherapy treatment.

9 Sep 2009

Mobile emergency alert system launched by Clearwave

The proliferation of GPS-enabled phones in recent years has allowed us to take yet another critical step toward push-button emergency location. But until recently, those tools have fallen short of the data emergency medical personnel need to successfully treat patients on-site, to notify next-of-kin and other important contacts, and to make informed decisions for patient transport.

9 Sep 2009

Parents use many food strategies to cope with work and family demands

Since most parents in the US are employed, there are competing demands on their time that can compromise food choices for themselves and their children. How parents cope with these demands and how work conditions are related to food choice coping strategies are the subjects of a study in the September/October issue of the Journal of Nutrition Education and Behavior.

9 Sep 2009

Web-based clinical support tool for gastric bypass and sleeve gastrectomy patients

Building on the success and popularity of REALIZE mySUCCESS(R) for REALIZE(TM) Band patients, Ethicon Endo-Surgery, Inc. announced today it will expand availability of the Web-based clinical support tool to gastric bypass and sleeve gastrectomy patients.

9 Sep 2009

Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma

BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.

9 Sep 2009

FDA approves ISTA's Bepreve for treating ocular itch

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the U.S. Food and Drug Administration (FDA) has approved Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis in patients two years of age and older.

9 Sep 2009

Phenotype microarrays compare growth characteristics of pathogenic and non-pathogenic E. coli

Dr Karin Heurlier and colleagues at the Universities of Nottingham and Birmingham in conjunction with Biolog Inc of California USA, used powerful high throughput analytical tools (phenotype microarrays) that enabled them to compare about 2000 growth characteristics of several pathogenic (disease-causing) E. coli with a non-pathogenic laboratory E. coli strain.

9 Sep 2009

FDA approves Cochlear's Nucleus 5 System

Cochlear, the global leader in implantable hearing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved the Nucleus((R) )5 System for adults and children with severe-to-profound hearing loss.

9 Sep 2009

Mid-Atlantic region’s first laparoscopic gastric banding surgery performed at AEHN

Albert Einstein Healthcare Network (AEHN) announced today that its chief bariatric surgeon successfully performed the Mid-Atlantic region’s first laparoscopic gastric banding surgery, which is performed through a single incision in a patient’s umbilicus (or belly button), ultimately resulting in the potential for no visible scar.

8 Sep 2009

African health ministers adopt resolutions to improve health as WHO regional meeting closes

At the conclusion of the 59th session of the WHO Regional Committee for Africa, African health ministers agreed on four resolutions that aim to improve health on the continent, the Guardian reports.

8 Sep 2009

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.

8 Sep 2009

FDA undecided on safety guidelines for hydroquinone use

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

8 Sep 2009

Protalix receives orphan drug designation for prGCD

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company’s proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

8 Sep 2009

Shire's assistance helps Gaucher patients manage imiglucerase supply shortage

Shire plc, the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide.

8 Sep 2009

Fundraising event to benefit the Centre for Addiction and Mental Health

Tickets are now on sale for the third annual Queen Street Unmasked, a gala fundraiser on Wednesday, Oct. 14 to benefit the Centre for Addiction and Mental Health (CAMH).

8 Sep 2009